News

Prexton opts for Parkinson drug
Enlarge image

BusinessFranceSwitzerland

Prexton opts for Parkinson drug

23.01.2013 - Merck-Serono spin-out Prexton Therapeutics has secured an exclusive licence option on a Parkinson candidate of Domain Therapeutics.

The Strasbourg-based company's metabotropic glutamate receptor 4 (mGluR4) Positive Allosteric Modulator (PAM) was previously developed through a licensing and collaboration agreement signed between Domain and Merck Serono in January 2011. Prexton was spun out following Merck Serono restructuring, taking on the mother company's R&D portfolio in the field of Parkinson's disease.

Under the terms of the agreement signed between Domain and Prexton, Prexton will benefit from an exclusive license option to progress two mGluR4 PAM drug candidates into clinical development.  mGluR4 is a glutamate receptor, member of the G-Protein Coupled Receptor (GPCR) family and is believed to be a potential therapeutic target for Parkinson’s disease. Allosteric modulation of mGluR4 receptors is thought to exert regulatory activity onglutamate-mediated neurotransmission

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/prexton-opts-for-parkinson-drug.html

EU

04.09.2015 Crowdfinancing has just recently emerged as a financing instrument in the Life Sciences. A new report lists 42 European companies in the sector that have raised a total of almost €23m.

DiabetesFrance

01.09.2015 Sanofi is partnering up with Google’s life sciences team with an ambitious goal: to change the face of diabetes management.

M&ASwitzerlandFrance

31.08.2015 In order to boost its active cosmetic ingredients business, the Swiss flavour and fragrance giant Givaudan has acquired Volketswil-based Induchem Holding and all its subsidiaries.

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • SAREUM HOLDINGS (UK)0.26 GBP18.18%
  • EVOCUTIS (UK)0.19 GBP5.56%
  • CERENIS THERAPEUTICS HOLDING SA (F)13.43 EUR5.09%

FLOP

  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • 4SC (D)3.17 EUR-8.12%
  • STALLERGENES (F)47.02 EUR-6.07%

TOP

  • KARO BIO (S)41.10 SEK2375.9%
  • BIOTECH PHARMACON (N)16.10 NOK69.5%
  • TIGENIX (B)1.18 EUR66.2%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • NEUROVIVE PHARMACEUTICAL AB (S)11.30 SEK-48.6%
  • THROMBOGENICS (B)2.85 EUR-43.0%

TOP

  • KARO BIO (S)41.10 SEK4570.5%
  • ADOCIA (F)87.80 EUR425.4%
  • GALAPAGOS (B)51.42 EUR315.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • NEUROVIVE PHARMACEUTICAL AB (S)11.30 SEK-82.3%
  • BIOTEST (D)19.82 EUR-77.1%

No liability assumed, Date: 04.09.2015